Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children
- 24 April 2018
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 32 (7) , 851-860
Abstract
Objective: To determine the magnitude and persistence of quadrivalent human papillomavirus (HPV)16 and HPV18 B-cell and T-cell memory after three or four doses of quadrivalent HPV vaccine (QHPV) in HIV-infected children. Methods: Seventy-four HIV-infected children immunized with four doses and 23 with three doses of QHPV had HPV16 and HPV18 IgG B-cell and IFNγ and IL2 T-cell ELISPOT performed at 2, 3.5 and 4–5 years after the last dose. Results: HPV16 and HPV18 T-cell responses were similar in both treatment groups, with higher responses to HPV16 vs. HPV18. These HPV T-cell responses correlated with HIV disease characteristics at the study visits. Global T-cell function declined over time as measured by nonspecific mitogenic stimulation. B-cell memory was similar across treatment groups and HPV genotypes. There was a decline in HPV-specific B-cell memory over time that reached statistical significance for HPV16 in the four-dose group. Conclusion: B-cell and T-cell memory did not significantly differ after either three or four doses of QHPV in HIV-infected children. The clinical consequences of decreasing global T-cell function and HPV B-cell memory over time in HIV-infected children requires further investigation.Keywords
This publication has 38 references indexed in Scilit:
- HIV Infection, Immunodeficiency, Viral Replication, and the Risk of CancerCancer Epidemiology, Biomarkers & Prevention, 2011
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccineHuman Vaccines, 2011
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBritish Journal of Cancer, 2011
- Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assaysJournal of Immunological Methods, 2010
- Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United StatesCancer, 2010
- Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected MenThe Journal of Infectious Diseases, 2010
- Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years OldJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus–Positive WomenThe Journal of Infectious Diseases, 2010
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyThe Lancet Oncology, 2009
- Antiretroviral Therapy and the Clinical Evolution of Human Papillomavirus–Associated Genital Lesions in HIV‐Positive WomenClinical Infectious Diseases, 2004